Bayer Contemplates Breakup Amidst Poor Performance and Job Cuts
Originally Published 2 years ago — by Endpoints News
Bayer plans to overhaul its business structure and reduce management layers in response to declining performance, with CEO Bill Anderson stating that zero cash flow despite nearly €50 billion in revenue is unacceptable. While the company's Q3 pharmaceutical sales remained steady at €4.53 billion, its share price has dropped by 20% since last year.